Latest News for: gip

Edit

T�Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing

Nasdaq Globe Newswire 09 Oct 2026
T�Time Health Inc., the telehealth brand at ttime.men, has launched cash-pay compounded injectable semaglutide and tirzepatide with one published rate regardless of prescribed dose ... .
Edit

T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing

Killeen Daily Herald 09 Oct 2026
Austin, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- T·Time Health Inc., the telehealth brand at ttime.men, has launched ....
Edit

Ask Mr. Fisher (almost) anything on the GIPS Cast

Kearney Hub 07 Oct 2026
Superintendent Matt Fisher joins "The GIPS Cast" mailbag episode to answer community questions on snow days, a second high school, four-day weeks, and student success ... .
Edit

AT&T to form fiber joint venture with BlackRock's GIP, CPP Investments

The Lufkin News 06 Oct 2026
Oct 6 (Reuters) - AT&T said on Tuesday it would form a fiber joint venture with BlackRock's Global Infrastructure Partners and Canada Pension Plan Investment Board, as America's largest fiber provider ....
Edit

EASD 2026 | 19.3% WEIGHT LOSS AT WEEK 48 WITH A GENERALLY FAVORABLE GASTROINTESTINAL TOLERABILITY. PHASE III (LIGHTEN) DATA OF THE DUAL-BIASED GLP-1/GIP RECEPTOR AGONIST OLATOREPATIDE PRESENTED AS A LATE-BREAKING ORAL PRESENTATION (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 05 Oct 2026
PHASE III (LIGHTEN) DATA OF THE DUAL-BIASED GLP-1/GIP RECEPTOR AGONIST OLATOREPATIDE PRESENTED AS A LATE-BREAKING ORAL PRESENTATION ... Olatorepatide Injection is a once-weekly subcutaneous dual-biased GLP-1/GIP receptor agonist.
Edit

No casino money goes directly to GIPS, Fisher says

Lincoln Journal Star 03 Oct 2026
Why doesn’t casino money reduce the property tax asking for Grand Island Public Schools? Because GIPS doesn’t get any of that money directly ... .
Edit

19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD

PR Newswire 02 Oct 2026
A dual-biased GLP-1/GIP receptor agonist, Olatorepatide offers a novel signaling pathway approach to overcoming the challenge of achieving both weight loss efficacy and tolerability.
Edit

TotalEnergies Signs an Agreement with GIP on African Energy Infrastructure Assets (Form 6-K) (TotalEnergies SE)

Public Technologies 01 Oct 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134856692) .
Edit

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP ...

Nasdaq Globe Newswire 30 Sep 2026
Kailera today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program ... .
Edit

Most powerful obesity drug yet: People lost up to 25% of weight in trial

Ars Technica 30 Sep 2026
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations ... 4 mg of retatrutide, 9 mg, 12 mg, or a placebo.
Edit

Column from GIPS superintendent: Budget, buildings and healthy cash reserves

The Grand Island Independent 29 Sep 2026
"This loss in funding from the state, along with continued rising costs for staff and goods, and increased demand for special services, created a challenging budget environment." ... .
Edit

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Nasdaq Globe Newswire 29 Sep 2026
Novo and Hengrui Pharma enter 2.6 billion USD license agreement for obesity and diabetes pill that could potentially be taken only once every week ... .
Edit

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual

Hastings Tribune 29 Sep 2026
HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties ... .
Edit

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Morgan Citizen 29 Sep 2026
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties ... .
Edit

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 (Novo Nordisk A/S)

Public Technologies 29 Sep 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134773263) .

Article Search

tools
×
×
×
×